AMP is WAC (and other thoughts)
Latest posts and updates
ABOUT AMP is WAC
Average Manufacturer Price (AMP) is not equal to Wholesale Acquisition Cost (WAC), but it is close. And since the whole world of health policy and reimbursement is a bit WAC-y, that’s what we’re calling this update/blog part of the site. All of the opinions and thoughts presented here are our own and not the views of clients or affiliates.
-
Caught my eye — 1/24/25
Read more: Caught my eye — 1/24/25I am pretty sure January is actually the whole first half of the year. Bears and hibernation might have the right idea. Old Hat Already: I hit send last week and the Centers for Medicare & Medicaid Services (CMS) released the list of 2027 Medicare negotiated drugs. Overall it felt like just another announcement with…
-
340B, Caught my eye, Inflation Reduction Act, Medicare Negotiation, Medicare Part D, Pharmacy Benefit ManagersCaught my eye — 1/16/25
Read more: Caught my eye — 1/16/25Tell me a Story. If you’ve been reading my stuff for a while, you know that I love a good lawsuit filing. Sometimes the lawyers get a little spicy. Teva filed suit against the federal government for the Inflation Reduction Act and it has a few gems: The suit is different from others that have…
-
340B, Caught my eye, Drug Prices, Healthcare Costs, Inflation Reduction Act, Medicare Negotiation, Medicare Part D, Pharmacy Benefit ManagersCaught my eye — 1/10/25
Read more: Caught my eye — 1/10/25There are some weeks where your long-term success could be impacted if you’re not on top of what’s happening, this isn’t one of those weeks. But these things are cumulative so, if need help on the regular with strategy and health policy (like figuring out what you need to pay attention to, help understanding the…
-
Caught my eye — 12/20/24
Read more: Caught my eye — 12/20/24Is anybody out there? It seems like everyone has disappeared for the rest of the year. And who can blame them? A few odds and ends caught my eye as I got ready to wrap up this year… Rebatable: 2025 should be interesting with now 4 companies pursuing the rebate model and suing the government.…
-
Nurturing the Potential of Biosimilars
Read more: Nurturing the Potential of BiosimilarsIs the biosimilar market a success? Almost ten years since the first U.S. biosimilar launch, Apteka released a paper looking at the current biosimilar landscape, questions whether it has met its objectives and proposes policy solutions for securing the future biosimilars. Although biosimilar take-up has been gradual, with each biosimilar approved – particularly provider-administered drugs…
-
Caught my eye — 12/13/24
Read more: Caught my eye — 12/13/24Methodology Matters. The Institute for Clinical and Economic Review (ICER) released their annual Unsupported Price Increase report and I find the whole process maddening. The inflationary metric they used was medical, not general (CPI-U). You might think that didn’t matter but it does. You know what medical inflation was? 0.48%. So anything over 2.48% increase…
-
Caught my eye — 12/6/24
Read more: Caught my eye — 12/6/24When your job is to stay on top of the news but you also just want to turtle a little bit, there are challenges that eventually have to be faced. Skimming the news, here is what caught my eye… 340B Bonanza. I have been devouring the 340B coverage of J&J, Lilly and BMS suing the…
-
Caught my eye, Drug Prices, Healthcare Costs, Inflation Reduction Act, Medicare Negotiation, Medicare Part DCaught my eye — 11/22/24
Read more: Caught my eye — 11/22/24As we look ahead to next week and Thanksgiving, I have to say thank you to you for subscribing and reading. I got the stuffing knocked out of me this summer but knowing that this group of subscribers hangs in there and continues to read is nice. As I look ahead to the next year,…
-
Caught my eye — 11/15/24
Read more: Caught my eye — 11/15/24Broken Crystal Ball. Does the knowledge that RFK Jr might be heading up the Department of Health and Human Services get me any closer to guessing what might happen in the next 2 – 3 years for pharmaceutical health policy? Nope. But it wouldn’t seem like it would be good for innovation. NIH grants? Developing…
-
Caught my eye — 11/8/24
Read more: Caught my eye — 11/8/24Some days you eat the bear and some days the bear eats you. Looking at Canada? No, not like that. JAMA featured a supply chain shortage look at the U.S. versus Canada. While not all of the lessons from Canada carry over (more flat bureaucracy because of connections between regulators and facilities) – they do…
Latest news
- Caught my eye — 1/24/25
- Caught my eye — 1/16/25
- Caught my eye — 1/10/25
- Caught my eye — 12/20/24
- Nurturing the Potential of Biosimilars
Categories
- 340B (31)
- Affordable Care Act (3)
- Alzheimer's (4)
- Biosimilars (19)
- Caught my eye (53)
- Chevron Deference (2)
- CMMI (8)
- Copay Accumulators (6)
- COVID (2)
- Drug Prices (28)
- Drug shortages (7)
- DTC (2)
- Employers (7)
- Generics (4)
- Health Equity (3)
- Healthcare Costs (24)
- ICER (7)
- Importation (2)
- Inflation Reduction Act (42)
- Insulin (4)
- IP (3)
- Long term care (1)
- Medicaid (3)
- Medicare Advantage (13)
- Medicare Negotiation (44)
- Medicare Part D (40)
- Medicare Transaction Facilitator (2)
- Medicare Transaction Facilitator (6)
- Obesity (18)
- On the Horizon (1)
- Orphan Drugs (2)
- Pharmacy Benefit Managers (25)
- Reference Pricing (4)
- State-based Reform (13)
- Uncategorized (4)
- Utilization Management (1)
- Vaccines (2)
- Value (8)